Meeting Coverage:

EURETINA Congress

EURETINA: 2018

Three Exciting New Drugs

Show Description +

Pravin U. Dugel, MD, reviews recent clinical trial data concerning three new drugs: brolucizumab (formerly RTH258, Novartis), a humanized single-chain antibody fragment; faricimab (formerly RG7716, Genentech), the first bispecific antibody designed for intraocular use; and RGX-314 (REGENEXBIO), a one-time subretinal treatment for wet age-related macular degeneration.

Posted: 9/22/2018

Up Next

Value of Recent Surgical Innovations

José García-Arumí, MD, PhD


The One Thing Every Doctor Can Do to Improve Efficiency in the Office

Nadia K. Waheed, MD, MPH, Pravin U. Dugel, MD

Disrupted Imaging on OCTA

Nadia K. Waheed, MD, MPH

Micropulse Laser in BRVO

Matteo Forlini, MD

Gene Therapy in Retinitis Pigmentosa

Robert E. MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci

Can We Get Smaller Than 27-Gauge Instrumentation?

José García-Arumí, MD, PhD, Robert E. MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci

Management of RVO

Anat Loewenstein, MD

Is There Any Hope for Dry AMD Patients?

Anat Loewenstein, MD, William Tucker, MD

Three Exciting New Drugs

Pravin U. Dugel, MD, reviews recent clinical trial data concerning three new drugs: brolucizumab (formerly RTH258, Novartis), a humanized single-chain antibody fragment; faricimab (formerly RG7716, Genentech), the first bispecific antibody designed for intraocular use; and RGX-314 (REGENEXBIO), a one-time subretinal treatment for wet age-related macular degeneration.

Posted: 9/22/2018


Please log in to leave a comment.

More From EURETINA: 2018 Coverage

Value of Recent Surgical Innovations

José García-Arumí, MD, PhD

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

Nadia K. Waheed, MD, MPH, Pravin U. Dugel, MD

Disrupted Imaging on OCTA

Nadia K. Waheed, MD, MPH